Additional Relevant Details has priced a registered public offering of an aggregate of approximately 28.6 million shares of common stock at a price to the public of $0.70 per share. Investors will also receive warrants to purchase up to an aggregate of approximately 28.6 million shares of common stock with an exercise price of $0.70 per share. The warrants are immediately exercisable and have a term of exercise of 12 months. The offering is expected to close on or about July 20, 2016, subject to the satisfaction of customary closing conditions.Rodman & Renshaw, a unit of H.C. Wainwright & Co., acted as sole book runner for the offering.The aggregate gross proceeds of the offering are anticipated to be approximately $20 million. After deducting the placement agent's commission and other estimated offering expenses payable by CytRx, the net proceeds to CytRx are anticipated to be approximately $18.3 million.  CytRx intends to use the net proceeds from the offering for working capital and general corporate purposes.